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Abstract
Importance
Decision support tools can assist people to apply population-based evidence on benefits
and harms to individual health decisions. A key question is whether “personalising” choice
within decisions aids leads to better decision quality.
Objective
To assess the effect of personalising the content of a decision aid for prostate cancer
screening using the Prostate Specific Antigen (PSA) test.
Design
Randomized controlled trial.
Setting
Australia.
Participants
1,970 men aged 40–69 years were approached to participate in the trial.
Intervention
1,447 men were randomly allocated to either a standard decision aid with a fixed set of five
attributes or a personalised decision aid with choice over the inclusion of up to 10 attributes.
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Outcome Measures
To determine whether there was a difference between the two groups in terms of: 1) the
emergent opinion (generated by the decision aid) to have a PSA test or not; 2) self-rated
decision quality after completing the online decision aid; 3) their intention to undergo
screening in the next 12 months. We also wanted to determine whether men in the person-
alised choice group made use of the extra decision attributes.
Results
5% of men in the fixed attribute group scored ‘Have a PSA test’ as the opinion generated
by the aid, as compared to 62% of men in the personalised choice group (χ2 = 569.38, 2df,
p< 0001). Those men who used the personalised decision aid had slightly higher decision
quality (t = 2.157, df = 1444, p = 0.031). The men in the personalised choice group made
extensive use of the additional decision attributes. There was no difference between the
two groups in terms of their stated intention to undergo screening in the next 12 months.
Conclusions
Together, these findings suggest that personalised decision support systems could be an
important development in shared decision-making and patient-centered care.
Trial Registration
Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12612000723886
Background
Clinical decision support for cancer screening tests
In an era of “shared decision-making” and “patient centered care,” it is widely accepted that cit-
izens have the right to make informed choices about all aspects of health care, including
whether or not to undergo screening tests [1, 2]. Information relevant to screening decisions
can, however, be complex and, as Entwistle et al [3] and others [4, 5] have noted, not everyone
either wants to or is capable of analyzing research data on the pros and cons of screening, pro-
cess numeric information on risk, deal with uncertainty relating to potential benefits and
harms, and then make an “informed” choice about screening. Paper-based, video and on-line
decision support tools can assist members of the public to interpret numeric information
(probability) on the risks and benefits of screening and deal with uncertainty. They do this by
providing a framework for analysis that reduces some of the cognitive demands of processing
information on probability [6].
The quality of decision aids
Not all decision aids are equally effective in assisting decision-making, and it is important that
their quality is assessed prior to implementation[7]. “Decision attributes” that might be used
to assess the quality of a decision aid include measures of knowledge and risk perception;
whether participants feel informed and clear about values; whether they feel certain about and
satisfied with a decision; whether they subsequently participate actively in decision-making;
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and whether clinician—patient communication is improved. Relevant outcome measures
include persistence with chosen therapy, quality of life, and healthcare costs [6].
The quality of decision aids can be enhanced, for example, by ensuring that they are suffi-
ciently detailed and that they contain explicit values clarification exercises [6]. There are, how-
ever, still many unanswered questions about the best way to design decision aids [6]. One
specific question about decision aids that remains unanswered is whether there is any benefit
in “personalising” choice within decision aids. That is, whether it is beneficial to allow partici-
pants to choose which factors are important to them in making decisions, and therefore which
attributes should be included in decision aids. The premise underpinning this approach, and
the starting point for shared decision-making and patient centered care, is that it is important
to focus on what individuals know best—their own values—and then to help them develop
their ability to express personal preferences in the context of making an informed health deci-
sion [8].
In this paper we report the results of a randomized controlled trial designed to assess the
effects of personalising the content of an online interactive decision aid for prostate cancer
screening using the Prostate Specific Antigen test (PSA). Specifically, we were interested in
exploring the effects of personalization on 1) the emergent, decision aid-generated, opinion as
to whether or not to pursue PSA testing, 2) the self-rated quality of the decision made, 3) the
process of reasoning about PSA testing that led to the particular opinion, and 4) the intention
to undergo screening in the next 12 months.
Prostate cancer screening and decision support
Many clinicians believe that prostate cancer is best detected as early as possible through screen-
ing of aymptomatic men, using prostate specific antigen (PSA) testing and/or digital rectal
examination (DRE). Although PSA is a non-specific biomarker, which can also be abnormal as
a result of other conditions such as infection, PSA screening (and/or DRE) are currently the
only methods available for screening for prostate cancer in asymptomatic men and routine
screening using PSA remains common. (While there are other tests and prediction tools for
prostate cancer, these serve different purposes. For example, Partin tables predict the final
pathology following prostatectomy based on preoperative variables. European Organization
for Research and Treatment of Cancer (EORTC) risk tables predict the likelihood of having
cancer in a biopsy based on PSA and other variables. Other factors, such as free PSA (fPSA)
and prostate volume, are also used subsequent to screening (using PSA or DRE) to predict the
likelihood of prostate cancer. None of these tests are screening tests. Other potential screening
tools include PSA isoforms, Prostate Cancer Antigen 3 (PCA3 or DD3) and magnetic reso-
nance imaging, however these have not yet been comprehensively evaluated and are not used
routinely for screening).
Despite the frequency with which PSA screening is conducted, evidence has emerged over
the past few years that questions the appropriateness of routine PSA screening for prostate can-
cer [9–11]. While some research suggests significant mortality reductions associated with PSA
screening, other research suggests there is no mortality reduction associated with screening
or at least not one that justifies the risks associated with testing and treatment. For example,
Andriole et al (2012), in an analysis of the 13 year follow-up of the Prostate, Lung, Colorectal,
and Ovarian (PLCO) trial, found no evidence of a mortality benefit for organized annual
screening compared to opportunistic screening (as part of usual care) [12]. In 2013, the authors
of a Cochrane Review concluded that PSA screening does not significantly reduce mortality,
and is often harmful [13].
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Despite this, there is evidence that routine PSA testing remains common in some popula-
tions. Williams et al (2010), for example, report PSA testing rates in UK general practices to be
1.4% (95% CI 1.1–1.6%) in men aged 45–49 years, but rising sharply to 11.3% (95% CI 10.0–
12.9%) in men aged 75–79 years (p-value for trend<0.001) [14]. A recent US study showed
that more than 50% of healthy men aged 65–74 years were screened in 2010 [15]. An Austra-
lian study of men under 55 years found that PSA testing increased by 146% between 2001 and
2008 [11].
In an effort to bridge the gap between evidence and practice, most major policymaking
organisations internationally now recommend against routine prostate cancer screening using
PSA [16–23]. If a man asks his doctor to be tested, then it is recommended that testing take
place only after a thorough process of shared decision-making and informed consent. Uro-
logical associations internationally often take a less definite position on screening, but they
too tend to recommend against general population screening programs, and emphasise the
need for shared decision making for men who are in high risk groups or who ask to be tested
[24, 25].
A number of decision support tools have been developed to facilitate this kind of shared
decision-making for prostate cancer screening. These include written, online and video materi-
als, which are sometimes combined with education and discussion sessions. Decision aids usu-
ally present information about the risks of prostate cancer, and the risks and benefits of various
relevant tests and treatments. The decision attributes that are most commonly included are the
perceived importance (or lack thereof) of: extending life; avoiding death from prostate cancer;
early diagnosis and treatment; avoiding urinary, bowel or sexual dysfunction stemming from
diagnosis and treatment; avoiding false positives resulting in unnecessary anxiety, tests (e.g.
biopsies) and treatments; avoiding false negatives and false reassurance (sometimes framed as
the importance of having an accurate screening test); being active in caring for one’s health;
having knowledge; having peace of mind; and being “safe” rather than “sorry” e.g. [26–35].
Numerous trials have been conducted into the effects of providing decision support for PSA
testing. These trials have generally found that men who use decision support tools are better
informed about prostate cancer and screening, more confident about their decision, less con-
flicted in their decision-making, and more likely to participate actively in decision-making.
They are also less likely to express an intention to be screened and, subsequently, less likely to
opt for PSA testing as part of routine care, although this is somewhat variable (e.g. it is less
likely to be the case for men who are specifically seeking screening services) [6, 26, 36–43].
Although there are numerous existing decision support tools for prostate cancer, which have
been compared to standard care and to each other, these tools all have in common that the
decision attributes are pre-defined and people using the tools have no choice but to consider all
attributes that are presented to them. In other words, they are not “personalised” in the sense
described previously. We therefore chose to develop and test the effects of a personalised deci-
sion aid for PSA screening.
Method
Phase 1: Developing a personalised decision aid for prostate cancer
screening
The Annalisa decision support platform. The personalised decision support tool that we
developed for prostate cancer screening used a software platform known as Annalisa—an
interactive decision aid template based on Multi Criteria Decision Analysis (MCDA) [44, 45].
This approach was developed in collaboration with clinicians and patients [44], and recognizes
that there are often multiple and competing criteria that drive decision-making. Methods
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applied within the MCDA framework assess the individual’s “trade offs” among these criteria
and then generate an “opinion” based on the trade offs that are made [46–48].
Annalisa, an example of a prescriptive decision aid, presents users with a set of relevant
decision attributes. They are then asked to indicate the relative importance or weight they wish
to attach to the attribute by dragging the cursor associated with each attribute to the left (lower
weight) or to the right (higher weight) on a “Weightings Panel.” If they want to see it, the par-
ticipant is also given pre-populated information (expressed as probabilities of particular out-
comes) about each attribute on a “Ratings Panel.” A bar graph is then generated on a “Scores
Panel” that shows the emergent opinion based on a summed multiplication for each option of
evidence ratings and the user’s weightings assigned to each attribute (Fig 1). An overall opinion
is then generated by the software, which is rated and ranked compared to other options. In this
study, the opinions generated were whether or not to undergo PSA testing. A more detailed
description and demonstration of Annalisa can be found at: healthedecisions.org.au.
Annalisa differs from standard decision aids (both descriptive and prescriptive) in that it
does not assume that participants know and understand risk (that is, probabilities that
express the chance of an event occurring). It is well recognized that statistical illiteracy and
“probability blindness” are major challenges in making informed health choices, and that
these are not easily remedied through more education and more transparent representation
of chance [4]. Rather than trying to simultaneously achieve statistical literacy and preference
elicitation, therefore, the Annalisa decision aid simplifies decision support to just one task—
asking the participant to express their importance weight for each attribute (benefit or harm)
related to the options. Information on the best available evidence for screening, expressed as
the probability of an event or outcome occurring, can be viewed online. However, the user
does not need to view this information in order to generate the score for each option. An
algorithm embedded in the decision aid automatically carries out the simple “expected value”
calculation, which involves multiplying the probability of the event occurring by the impor-
tance weight.
Phase 2: Randomized trial of the personalised decision aid
A pilot study was conducted to ensure that the tool was user-friendly and that men understood
the meaning of the 5 fixed and 5 additional attributes. Once the pilot study had been com-
pleted, 1,970 men were invited to participate in the study. Each participant was directed to an
online survey and asked to give consent to participate in the study. Upon consenting to partici-
pate, men who were eligible were block randomized by age group (40-49yrs, 50-59yrs or 60-
69yrs) to either: 1) the fixed attribute group (active comparator) or 2) the personalised choice
group (active intervention). Computer randomization was undertaken to enroll participants in
either the active comparator or active intervention group.
Online survey
An online survey was developed (with the PSA decision aid embedded within it) in order to
screen out candidates who did not meet the eligibility criteria and stratify people according to
age and risk of prostate cancer based on family history. The survey was identical for both trial
groups (S6 File). Participants were asked whether they had ever had a PSA test and when; the
likelihood they would consult a GP within the next 12 months about having a PSA test; as well
as information on their socio demographic characteristics and personal and family history of
prostate cancer, which were important for determining eligibility and probabilities of risk and
benefit.
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Fig 1. Demonstration of Annalisa decision tool for Prostate Cancer Screening.
doi:10.1371/journal.pone.0152999.g001
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Randomised trial
Two version of Annalisa were developed: (1) a fixed attributes version consisting of the five
fixed attributes: survival (lifetime), needless biopsy, and urinary, bowel and sexual functioning
problems, and (2) a personalised choice version consisting of the 5 fixed attributes plus 5 extra
attributes: quality of life, overdiagnosis, burden of treatment, burden to carers, and anticipated
regret. The process we used for personalising Annalisa is described in an E appendix (S10 File)
and the attributes as they were presented to the participants are illustrated in Fig 2.
Those in the fixed attribute group were directed immediately to the Annalisa decision aid
with its five pre-determined attributes, while those in the personalised choice group were first
asked to select as few or as many attributes as they wanted to from the 10 options described
above.
The ratings (probabilities) for each included attribute were personalised to each participant
based on their response to a survey question on the number of first-degree (male) relatives who
have been affected by prostate cancer, and their stated age group.
Trial participants in both groups were then asked to weight the importance of each of the
included attributes on a continuous scale from zero (no importance) to one (all important) in
the context of a hypothetical decision on whether to have a PSA test.
Outcome measures. The two main outcome measures of the study were the option rank-
ing (emergent opinion to have a PSA test or not have a PSA test as determined by the Annalisa
tool) and (self-rated) decision quality after completing the online decision aid for PSA screen-
ing. The decision quality instrument MyDecisionQuality (MDQ)[49] was used to assess deci-
sion quality. MDQ is a generic (as opposed to condition-specific) tool for assessing decisions
made using any form of decision technology. Like the PSA decision aid itself, MDQ uses the
principles of Multi-Criterion Decision Analysis (MCDA) to weight and rate eight elements of
decision quality, namely: perceived clarity about the nature of the available options, their
effects, their personal importance and their likelihood; perceived ability to trust the informa-
tion provided; perceived adequacy of support provided during decision making; perceived
sense of control over the decision; and perceived degree of commitment to acting on the deci-
sion [49]. The participant was responsible for both weighting the criteria of decision quality in
terms of their relative importance to them (prior to using the decision aid), and rating the qual-
ity of the decision just made according to these criteria (after completing the decision aid). A
full description of each decision quality attribute can be found in the online supplementary
material (S7 and S8 Files).
We were also interested in whether, and to what extent, men in the personalised choice
group made use of the extra decision attributes in addition to, or instead of, the five fixed attri-
butes and whether there was a difference between the two groups in terms of their intention to
undergo PSA screening (irrespective of whatever opinion had been generated by the aid).
Recruitment, sample size and study participants. A sample size of 699 in each of the two
arms of the trial was based on the number needed to detect a 0.15 difference in the mean Deci-
sion Quality (DQ) score that rejects the null hypothesis that the mean DQ scores are equal,
with probability (power) 0.8. The potential study population consisted of 130,000 people from
a market research company panel of Australians. To allow for non-consenters and men with
prostate cancer diagnoses and hence ineligible for PSA screening, 1,970 men were contacted, of
whom 1,447 eligible men consented to participate (73.5% response rate). Recruitment began
on June 3, 2011 and concluded on June 21,2011.
Statistical analysis. Univariate analysis was performed. Differences in PSA test opinions
(generated by the decision aid) and behavioral intentions between the two groups were com-
pared using chi-square tests (p-values reported). Differences in the mean Decision Quality
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scores between the two groups was tested using a t-test. The mean (SD) importance weights
(normalized) for each attribute in the decision aid were calculated and between group differ-
ences compared using a t-test.
The trial was approved by the University of Sydney Human Research Ethics Committee
(Protocol No.: 05–2011 / 13712) on 13 May 2011 and was included in the Australian New Zea-
land Clinical Trials Registry (ANZCTR) on 6 July 2012 (ACTRN: ACTRN12612000723886).
The authors confirm that all ongoing and related trials for this drug/intervention are registered.
All participants gave informed consent.
Results
A total of 1,970 men were invited to participate in the study. Of these, 1,010 were randomly
allocated to the fixed attribute group and 960 to the personalised choice group. A total of 767
and 744 men respectively consented to participate in the study. There were 40 men in the fixed
attribute group and 24 in the personalised choice group who were subsequently excluded
because they had prostate cancer or were unsure whether they had prostate cancer or not. The
final sample consisted of 727 men in the fixed attribute group and 720 men in the personalised
choice group. A summary of respondent characteristics and socio demographics is provided in
Table 1.
Survey results
There were no statistically significant differences between the two study groups in personal and
other socio demographic characteristics. The average time taken to complete the survey online
Fig 2. Description of attributes for the personalised decision aid.
doi:10.1371/journal.pone.0152999.g002
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Table 1. Respondent Characteristics.
All Fixed
Attributes
Personalised
Choice
n = 1447 n = 727
(50.2%)
n = 720
(49.8%)
n % n % n %
Age
40–49 years 591 40.8 282 38.8 309 42.9
50–59 years 487 33.7 248 34.1 239 33.2
60–69 years 369 25.5 197 27.1 172 23.9
Family history
None 1118 77.3 552 75.9 566 78.6
1 194 13.4 109 15.0 85 11.8
2 or more 14 1.0 5 0.7 9 1.3
Don't know 121 8.4 61 8.4 60 8.3
Previous PSA testing
Had a PSA test in past 12 months 393 27.2 209 28.8 184 25.6
Had a PSA test longer than 12 months age 205 14.2 101 13.9 104 14.4
Never had a PSA test 768 53.1 382 52.5 386 53.6
Don’t Know 81 5.6 35 4.8 46 6.4
General Health
Excellent 149 10.3 75 10.3 74 10.3
Very good 402 27.8 198 27.2 204 28.4
Good 587 40.6 302 41.5 285 39.7
Fair 232 16.1 118 16.2 114 15.9
Poor 75 5.2 34 4.7 41 5.7
Time since last visited doctor (GP)
Less than 2 weeks 363 25.1 173 23.8 190 26.4
2 weeks to 3 months ago 492 34.0 253 34.8 239 33.2
3 to 6 months ago 257 17.8 145 19.9 112 15.6
6 to 12 months ago 165 11.4 81 11.1 84 11.5
12 months or more 150 10.4 67 9.2 83 11.5
Never 8 0.6 4 0.6 4 0.6
Not sure 11 0.8 4 0.6 4 0.6
Health Cover (excluding Medicare)
Private health insurance with extras 551 38.8 279 39.1 272 38.6
Private health insurance without extras 94 6.6 45 6.3 49 7.0
Department of Veteran's Affairs card 36 2.5 14 2.0 22 3.12
Health care concession card 382 26.9 201 28.2 181 25.7
None of these 342 24.1 173 24.3 169 24.0
Don't know 14 0.99 2 0.3 12 1.7
Country of Birth
Australia 1091 75.4 541 74.4 550 76.4
New Zealand 49 3.4 25 3.4 24 3.3
UK or Ireland 145 10.0 75 10.3 70 9.7
Elsewhere in Europe 71 4.9 42 5.8 29 4.0
Elsewhere in World 91 6.3 44 6.1 47 6.5
Relationship Status
Married 768 53.1 393 54.1 375 52.1
(Continued)
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was 18.04 minutes for the fixed attribute group and 21:57 minutes for the personalised choice
group, reflecting the additional time required to consider, select and rate the importance of the
longer list of attributes in this arm.
Decision aid results
The two main outcome measures for the trial were (1) the screening opinion as generated by
the decision aid, and (2) the quality of the decision made using the aid (DQ) as measured on
the MDQ (MyDecisionQuality) continuous scale.
Effects on the PSA screening opinion. There was a very clear difference in PSA screening
opinion between the two groups. Only 4.7% of those in the fixed attribute (active comparator)
group had an opinion generated that was in favor of the PSA test, compared to 61.5% in the
personalised choice (active intervention) group (χ2 = 569.38, 2df, p< 0001). The difference in
this screening opinion was clearly driven by the inclusion of attributes that are typically not
measured in large randomized trials of cancer screening and testing, including overdiagnosis,
burden of treatment, burden to carers, and anticipated regret (Table 2).
Effects on decision quality. Respondent-rated decision quality was statistically signifi-
cantly lower for the fixed attribute group at 0.67 than for the personalised choice group at 0.69
(t = 2.157,df = 1444, p = 0.031). Thus we reject the null hypothesis that the mean Decision
Quality score is equal in both groups with probability (power) 0.8.
Other outcome measures. Number of attributes selected: Amongst the 720 respondents
in the personalised choice group, 342 (47.5%) included all ten attributes in the decision aid,
another 92 (12.8%) included nine attributes, 83 (11.5%) included eight attributes, 77 (10.7%)
included seven attributes, 58 (8%) included six attributes, and the remaining 68 (9.5%)
included five or fewer attributes in the decision aid.
Table 1. (Continued)
All Fixed
Attributes
Personalised
Choice
n = 1447 n = 727
(50.2%)
n = 720
(49.8%)
n % n % n %
De facto 149 10.3 83 11.4 66 9.2
Separated 70 4.9 23 3.2 47 6.3
Divorced 181 12.5 87 12.0 94 13.1
Widowed 25 1.7 14 1.9 11 1.5
Never married 254 17.6 127 17.5 127 17.6
Highest Qualiﬁcation
Higher deg./Postgrad diploma/Bachelors deg. 345 23.8 173 23.8 172 23.9
Undergraduate diploma/Associate diploma 262 18.1 128 17.6 134 18.6
Skilled/Basic vocational qualiﬁcation 480 33.2 255 35.1 225 31.3
Has qualiﬁcation but unsure about the level 71 4.9 32 4.4 39 5.4
No higher qualiﬁcations 289 20.0 139 19.1 150 20.8
Employment Status
Not in the labour force 445 30.6 231 31.8 214 29.7
Employed 835 57.5 418 57.5 417 57.9
Unemployed 155 10.7 70 9.6 85 11.8
Don't know 12 0.8 8 1.1 4 0.6
doi:10.1371/journal.pone.0152999.t001
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Reasons underpinning the opinion generated for or against PSA screening: In both
groups, survival (avoiding the loss of lifetime due to prostate cancer) received the highest
importance rating of all attributes. In the fixed attribute group, survival achieved a weighting of
0.35. This decreased to just 0.15 in the personalised choice group when other attributes were
also considered. The importance weights attached to these extra attributes were similar across
the board (Table 2).
Intention to have screening before and after using the decision aid:When asked at the
beginning of the survey (and before using the online decision aid) about the likelihood of hav-
ing a PSA test in the next 12 months, both groups reported similar levels of intention (60.8% of
men in the fixed attribute group and 58.1% of men in the personalised choice group stated they
were likely or very likely to have a PSA test in the next 12 months). Despite the fact that only
4.7% of those in the fixed attribute (active comparator) group subsequently had an opinion
generated from the aid in favor of PSA testing, almost as many men in the fixed attribute group
(59.5%) as in the personalised choice group (68.3%) stated they were likely or very likely to
have a PSA test in the next 12 months (Table 3). This suggests that even when men use decision
aids that produce an opinion against PSA testing, they are likely to opt for testing when asked
directly about their intentions.
Discussion
Summary
Our most important results can be summarized as follows: 1) personalising the choice of attri-
butes had a significant effect on the number of men for whom the decision aid generated an
opinion in favor of PSA testing; 2) the quality of the decision made (or opinion generated by
the aid) using the personalised decision aid was at least as good as, and possibly better than,
that made using the fixed decision aid; 3) in the personalised choice group, the significance of
overall survival was offset by other attributes including avoiding regret and carer burden,
which are not included as attributes in standard prostate screening decision aids. Men were,
therefore, choosing to minimize a potential loss as well as maximize the potential health gain
associated with PSA screening. Contrary to expectations, avoiding biopsy was not amongst the
most important factors for men deciding on PSA screening for either group; and 4) many men
Table 2. ImportanceWeights (normalized) for each Attribute.
Fixed Attributes Personalised Choice
n = 727 (50.2%) n = 720 (49.8%)
n % Mean (SD) n % Mean (SD) t stat (df) p-value
Avoiding (0–1):
Loss of Lifetime 726 100 0.354 (0.257) 635 88.2 0.148 (0.094) -19.16 (df 1359) <0.0001
Needless Biopsy 726 100 0.137 (0.121) 561 77.9 0.108 (0.062) -5.18 (df 1285) <0.0001
Bowel problems 726 100 0.168 (0.112) 661 91.8 0.121 (0.044) -10.08 (df 1385) <0.0001
Sexual problems 726 100 0.178 (0.154) 582 80.8 0.119 (0.062) -8.66 (df 1306) <0.0001
Urinary problems 726 100 0.163 (0.103) 650 90.3 0.118 (0.045) -10.25 (df 1374) <0.0001
Loss of health n.a. 658 91.4 0.122 (0.055)
Overdiagnosis n.a. 556 77.2 0.101 (0.052)
Regret n.a. 565 78.5 0.114 (0.045)
Treatment burden n.a. 554 76.9 0.101 (0.041)
Carer burden n.a. 554 76.9 0.109 (0.055)
doi:10.1371/journal.pone.0152999.t002
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for whom the opinion of the aid was against PSA screening stated, when asked directly, that
they still intended to undergo screening. The use of the decision aid in both fixed and personal-
ised forms did not, therefore, have a predictable impact on intended prostate cancer screening
behavior.
Limitations
The main purpose of this study was to test the impact of personalising a decision aid developed
specifically for prostate cancer screening. The generalizability of the results are limited by (a)
the disease specific nature of the study, and (b) that group averages do not necessarily correlate
with the individual’s screening choice. A further limitation is that we were unable to follow up
actual screening behavior of the participants after completing the survey.
Practical implications
Implications for decision support. Our finding that men in the personalised choice
group were often just as concerned, or more concerned about factors such as avoiding regret
and carer burden as they were about were avoiding loss of life, needless biopsy or the burdens
of treatment, provides support for extending the set of regular criteria used in such decision
aids, and for allowing users to select those that are most significant to them. After all, decision
aid-guided shared decision-making will only have resonance if clinicians and patients know
which factors are most salient to the patient in any given context. This view is further sup-
ported by the finding that personalising the prostate screening decision aid had no adverse
impact on self-rated decision quality.
The finding that many men (in both groups) whose use of the aid generated an opinion
against PSA testing still stated an intention to undergo screening has implications for the utility
Table 3. PSA test preferences and intentions.
Fixed
Attributes
Personalised Choice
n = 727
(50.2%)
n = 720 (49.8%)
n % n % Chi-square test stat
(df)
p-value
Highest scoring option
Have a PSA test 34 4.7 443 61.5 569.38 (df 2) p<0.0001
Do not have a PSA test 692 95.2 256 35.6
Indifferent 1 0.14 21 2.9
Likelihood of consulting GP about PSA testing in next 12 months PRIOR to
seeing decision aid
Very Likely 227 31.2 205 28.5 3.10 (df 3) p = 0.3763
Likely 187 29.6 213 29.6
Unlikely 244 33.6 239 33.2
Very Unlikely 69 9.5 63 8.8
Likelihood of consulting GP about PSA testing in next 12 months AFTER seeing
decision aid
Very Likely 219 30.1 237 32.9 12.75 (df 3) p = 0.0052
Likely 214 29.4 255 35.4
Unlikely 228 31.3 180 25.0
Very Unlikely 66 9.1 48 6.7
doi:10.1371/journal.pone.0152999.t003
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of decision aids in general. This is not to say that decision aids are useless, but rather that they
are what their name suggests—decision aids—aimed at facilitating communication, informing
and assisting people to feel confident in the decisions they make. They are not, and should not
be mistaken for, tools that can “change people’s minds” or predict their ultimate intentions and
actions.
It is, however, noteworthy that, while the decision aid had little impact on the intention to
undergo screening, there was much less of a disjunction between opinions as generated by the
decision aid and stated intentions in the personalised choice group than in the fixed attributes
group (In the fixed attribute group, 5% of men had an opinion generated to have PSA testing
and 59.5% stated that they were likely or very likely to undergo testing in the next 12 months;
in the personalised choice group, 62% of men had an opinion generated to have PSA testing
and a similar percentage of 68.3% stated they were likely of very likely to be tested in the next
12 months). This finding suggests that personalising decision aids may create a higher degree
of congruence between the opinions generated by decision tools and actual behavior. More-
over, these findings suggest that personalised decision aids might be better tools for facilitating
communication and decision-making than fixed attribute aids.
Implications for policy. Our findings provide clear justification for further investigation
of the merits of personalised decision aids, but their broader policy implications are more com-
plicated. While both evidence-based medicine and patient-centered care emphasize the impor-
tance of factoring patient or community preferences into decision-making, neither paradigm
explains what to do when these preferences (expressed through decision aid-generated opin-
ions and/or stated intentions) conflict with scientific evidence and policy guidance.
On the one hand, it could be argued that we should accept any preferences that men express,
even if these go against current policy recommendations. On the other, while it is desirable to
provide health care that is consistent with expressed preferences, this is not the only consider-
ation for those providing care or making health care policy decisions. There are at least three
reasons for, on occasions, overriding patient or community preferences.
First, some degree of “soft paternalism” is inevitable in medical and public health practice.
While patients and communities are encouraged to make autonomous decisions about treat-
ment, this occurs within parameters of evidence-based “best practice” as determined by clinical
and public health practitioners. Second, resource allocation issues cannot be ignored when
making health care policy. In the case of PSA screening, it is essential to consider both con-
sumer preferences and the costs to the community of the testing itself and the unnecessary
interventions that might result from systematic “over-diagnosis.” Third, patient and commu-
nity preferences might be strongly expressed and compelling, but they may not be fully
“rational.”We know, for example, that people often make decisions on the basis of previous
decisions and experiences. Of course decisions based on previous experience should not be dis-
missed as “irrational,” but evidence of this kind of reasoning adds a layer of complexity to the
interpretation of preferences.
These are the reasons why clinicians and policy makers face major challenges in applying
population-level evidence to preference-sensitive decisions. Matters are complicated further by
the fact that it is very difficult to take away clinical options when they are already funded and/
or highly publicized, as in the case of PSA testing and many other screening tests [50, 51].
The policy implications of our findings thus depend on how clinicians and policy makers
choose to balance evidence against patient and community preferences in the context of estab-
lished clinical and public health practices. What seems clear, however, is that decision-making
will need to be individualised no matter how apparently compelling a policy directive might be,
and this might be aided by the use of personalised decision aids.
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Conclusion. Personalising a decision-aid for prostate cancer had a significant impact on
the opinion generated by the aid regarding PSA screening, on the reasoning underpinning
these opinions, and on the congruence between decision aid-generated opinions and stated
behavioral intentions, without impacting negatively on self-rated decision quality. Our findings
provide strong support for further development and investigation of personalised decision-
aids. Our findings also demonstrate the complexity of clinical and public health communica-
tion and health-related decision-making, and the need for ongoing reflection on how to accom-
modate expressed patient and community preferences within the frameworks of evidence-
based medicine and public health.
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